REVIEW

Defining the functional states of Th17 cells [version 1; peer review: 3 approved]

Youjin Lee¹, Vijay Kuchroo^{1,2}

¹Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, MA, 02115, USA

²Genomic and Biotechnology Section, Faculty of Science, King Abdulaziz University, Jeddah, 21589, Saudi Arabia

V1 First published: 28 May 2015, 4(F1000 Faculty Rev):132
<https://doi.org/10.12688/f1000research.6116.1>
 Latest published: 28 May 2015, 4(F1000 Faculty Rev):132
<https://doi.org/10.12688/f1000research.6116.1>

Abstract

The molecular mechanisms governing T helper (Th) cell differentiation and function have revealed a complex network of transcriptional and protein regulators. Cytokines not only initiate the differentiation of CD4 Th cells into subsets but also influence the identity, plasticity and effector function of a T cell. Of the subsets, Th17 cells, named for producing interleukin 17 (IL-17) as their signature cytokine, secrete a cohort of other cytokines, including IL-22, IL-21, IL-10, IL-9, IFN γ , and GM-CSF. In recent years, Th17 cells have emerged as key players in host defense against both extracellular pathogens and fungal infections, but they have also been implicated as one of the main drivers in the pathogenesis of autoimmunity, likely mediated in part by the cytokines that they produce. Advances in high throughput genomic sequencing have revealed unexpected heterogeneity in Th17 cells and, as a consequence, may have tremendous impact on our understanding of their functional diversity. The assortment in gene expression may also identify different functional states of Th17 cells. This review aims to understand the interplay between the cytokine regulators that drive Th17 cell differentiation and functional states in Th17 cells.

Keywords

Th17 , T helper cells , inflammation , cytokine signaling

Open Peer Review

Approval Status

	1	2	3
version 1 28 May 2015			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Richard Flavell**, Yale School of Medicine, Connecticut, USA
Nicola Gagliani, Yale School of Medicine, Connecticut, USA
2. **Jagadeesh Bayry**, French National Institute of Health and Research, Paris, France
3. **Dan R. Littman**, New York University School of Medicine, New York, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Vijay Kuchroo (vkuchroo@evergrande.hms.harvard.edu)

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2015 Lee Y and Kuchroo V. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Lee Y and Kuchroo V. **Defining the functional states of Th17 cells [version 1; peer review: 3 approved]**
F1000Research 2015, 4(F1000 Faculty Rev):132 <https://doi.org/10.12688/f1000research.6116.1>

First published: 28 May 2015, 4(F1000 Faculty Rev):132 <https://doi.org/10.12688/f1000research.6116.1>

T helper subsets and links to autoimmune inflammation

CD4 T cells are essential architects of host immune defense against pathogens^{1,2}. Collectively, their effector function is mediated in part by a compilation of cytokines that directs differentiation, migration, homeostasis, regulation, and inflammation. Initially, CD4 T helper (Th) cells were grouped into two distinct subsets defined by production of unique cytokines: type 1 helper T cells (Th1) produce IFN γ as their signature cytokine and mediate immune responses against intracellular pathogens, and type 2 helper T cells (Th2) secrete interleukin (IL)-4, IL-5 and IL-13 and drive immune responses against extracellular pathogens, like parasites³. In recent years, the number of unique subsets has grown to include IL-9-producing Th9, follicular T helper cells (Tfh) and IL-17-producing Th17, as well as three subsets of T cells that regulate immune responses, including Type 1 regulatory cells (Tr1), follicular T regulatory cells (Tfr) and T regulatory cell (Tregs) (Figure 1)⁴⁻⁶. Each of the effector subsets is not only critical for orchestrating a proper immune response against specific pathogens but is also a major contributor in the pathogenesis of a number of autoimmune inflammatory diseases⁷.

For a number of years, IL-12-induced Th1 cells were thought to be the main drivers of autoimmunity, based on the findings that IFN γ -secreting CD4 T cells were frequently found at the site of inflammation and treatment with IFN γ led to exacerbated disease in multiple sclerosis patients^{8,9}. IL-12 is a heterodimeric cytokine composed of two subunits, IL-12p35 and IL-12p40, and is a critical factor for the differentiation of Th1 cells^{10,11}. CD4 T cells express a heterodimeric IL-12 receptor (IL-12R) composed of IL-12R β 1 and

IL-12R β 2 subunits^{12,13}. Upon exposure to IL-12, the master transcription factor *Tbx21* is induced, which transactivates IFN- γ , and the cells differentiate into Th1 cells^{14,15}. The importance of Th1 cells in autoimmune diseases was further supported by findings that protection from experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, was observed upon neutralization with anti-IL-12p40 or in IL-12p40^{-/-} mice^{16,17}. However, it became clear that Th1 cells may not be the exclusive drivers for autoimmunity when it was discovered that mice lacking critical components of the Th1 differentiation pathway, such as IFN γ , IFN γ R, IL-12R β 2, and IL-12p35, were highly susceptible to EAE, suggesting that Th1 cells may even be protective in autoimmune diseases¹⁸⁻²².

Discovery of IL-23- and Th17-associated pathogenic inflammation

In the late 1990s, a novel cytokine called IL-23 that belongs to the IL-12 family of cytokines was discovered²³. Interestingly, similar to the functional IL-12 cytokine, IL-23 had an IL-23 p19 subunit, which combined with the IL-12 p40 subunit of IL-12, to develop a functional heterodimeric cytokine²⁴. Loss of either IL-23 p19 or IL-12 p40 chains made mice highly resistant to the development of EAE and other autoimmune diseases, suggesting that IL-23 is a cytokine critical for development of autoimmunity^{17,25,26}. However, unlike IL-12, IL-23 did not induce IFN γ production from naïve CD4 T cells^{24,27}, but it was suggested that IL-23 may be critical for the generation of IL-17-producing Th17 cells. A series of *in vitro* studies showed that IL-23 could not induce differentiation of naïve T cells into IL-17-producing Th17 cells. In fact, it was discovered

Figure 1. The diversity of CD4 subsets. CD4 T helper subsets identified with differentiating conditions as well as the signature cytokines they are known to produce. Th17 cells are further subtyped based on cytokine conditions that define pathogenic *versus* non-pathogenic states.

that the receptor for IL-23 was not even expressed on naïve CD4 T cells, suggesting that other cytokines besides IL-23 may be critical for the generation of Th17 cells^{28–30}. In fact, we³¹ and others^{32,33} showed that Th17 cells are differentiated in the presence of TGF- β 1 and IL-6, which resulted in the induction of a unique master transcription factor called ROR γ t. While IL-23 was not required for the differentiation of Th17 cells, it was revealed to be a critical factor for stabilization of the Th17 phenotype and in evoking pathogenic phenotype in Th17 cells. With ensuing studies it became clear that IL-23, not IL-12, was the critical cytokine for driving autoimmune inflammation. IL-23p19^{-/-}, IL-12p40^{-/-} and IL-23R^{-/-} mice^{17,25,26} were completely protected from developing a number of murine models of autoimmune diseases including EAE, psoriasis, and colitis. Consistently, Genome Wide Association Scans have reported a strong genetic linkage to single nucleotide polymorphisms (SNP) in IL-23 or IL-23R, with increased susceptibility to several human autoimmune diseases^{34–40}. However, the clearest role of Th17 cells in human autoimmune diseases was supported by clinical studies where neutralization of IL-17 by an anti-IL-17 antibody (Secukimumab) resulted in clinically beneficial results in a number of human autoimmune diseases, including psoriasis, ankylosing spondylitis, and multiple sclerosis^{41–45}.

Heterogeneity within the Th17 subset

Although Th17 cells have become synonymous with autoimmune tissue inflammation, it is now clear that not all Th17 cells are pathogenic or induce tissue inflammation⁴⁶. In human inflammatory bowel diseases (IBDs), neutralization of IL-17 or blockade of IL-17 receptor (IL-17Ra) resulted in disease exacerbation, suggesting a possible protective role by Th17 cells⁴⁷. IL-17-producing T cells that line the gut mucosa do not induce inflammation but have been shown to be necessary to maintain the barrier function of the gut⁴⁸. Commensal bacteria in the gut may play a critical role in the generation of Th17 cells in the lamina propria and, indeed, there is an absence of IL-17-producing cells in the lamina propria of the small intestines in germ-free mice^{49,50}. There is also evidence suggesting that IL-17 is required to prevent pathologic gut inflammation in a CD4 T cell-mediated transfer model of colitis, as cells lacking the capacity to produce IL-17, or the lack of IL-17R in recipient mice, resulted in exacerbated colitis^{51,52}. These studies alluded to a rather novel concept: that Th17 cells are not uniform in function. In fact, we⁵³ and others^{54,55} have shown that Th17 cells come in two flavors: one in which they cause pathogenic tissue inflammation and autoimmune disease and the other that is non-pathogenic, in that they fail to provoke autoimmunity, especially in murine T cell models of inflammatory disease (Figure 1)^{53–55}. Th17 cells differentiated in the presence of TGF- β 1 and IL-6^{56,57} co-produce IL-17 with IL-10, do not induce tissue inflammation, and in fact may inhibit autoimmune inflammation, and thus are characterized as “non-pathogenic” Th17 cells⁵⁵. However, upon exposure to IL-23, a “switch” occurs in the Th17 cell transcriptome, which not only allows for stabilization of the Th17 phenotype but also converts non-pathogenic Th17 cells to become pathogenic^{53,58}. These IL-23 experienced Th17 cells have been shown to promote destructive inflammation in numerous T cell-dependent murine models of autoimmunity^{53,58}. IL-23 inhibits IL-10 production and instead promotes secretion of IL-22 and GM-CSF, suggesting that IL-23 drives the development of Th17 cells with unique functional properties^{59–61}. This raises an important question: how does IL-23

induce pathogenicity in Th17 cells? Our studies revealed that IL-23 mediates important changes in the transcriptome of differentiating Th17 cells⁵³. Besides the induction of a number of unique transcription factors, IL-23 induces TGF- β 3 production in developing Th17 cells⁵³. We showed that TGF- β 3 together with IL-6 *in vitro* induces differentiation of pathogenic Th17 cells, without any need for further exposure to IL-23⁵³. Similarly, John O’Shea⁵⁴ and Chen Dong’s⁶² groups showed that naïve T cells exposed to IL-1 β , IL-6 and IL-23 could induce Th17 cells that were highly pathogenic. Thus, by varying the cytokine cocktails *in vitro*, both pathogenic and non-pathogenic Th17 cells can be generated. Based on these observations, we undertook a systematic transcriptome analysis of Th17 cells in order to develop a novel gene signature that functionally distinguishes Th17 subsets.

Transcriptional gene signatures for pathogenic Th17 cells

When we compared the gene expression profiles of all known possible *in vitro* differentiation combinations that induce pathogenic and non-pathogenic Th17 cells, we found 434 genes that were differentially expressed between these different Th17 subtypes⁵³. Of the 434 genes, 233 genes were differentially expressed between highly pathogenic and non-pathogenic Th17 cells⁵³. Based on the biological function, we identified a representative subset of 23 genes that was highly suggestive of driving pathogenicity⁵³. Pathogenic Th17 cells induced expression of various effector molecules that have been shown to be pro-inflammatory, such as *Cxcl3*, *Ccl4*, *Ccl5*, *Csf2* (GM-CSF), *Il3* (associated with *Csf2*), *Il22*, *Gzmb* (Granzyme B) and, interestingly, transcription factors that are associated with the Th1 phenotype such as *Tbx21* (Tbet) and *Stat4*⁵³. Conversely, non-pathogenic Th17 cells revealed a gene signature that included molecules associated with regulation, such as *Il10* and transcription factors that regulate IL-10 production, such as *Ahr* and *Maf* in addition to *Ikzf3* (Aiolos)⁵³. In addition, non-pathogenic Th17 cells express *Il1rn* (IL-1R antagonist) which might antagonize functions of IL-1 in differentiating Th17 cells into a pathogenic phenotype⁵³. Based on the comparative gene expression profiles between pathogenic and non-pathogenic Th17 cells, our group identified a gene signature that may confer pathogenic phenotype to Th17 cells⁵³.

The dichotomous nature of Th17 cells may not be a mere *in vitro* cytokine artifact but may have occurred naturally as a consequence of evolutionary pressures to defend against different types of pathogens. Federica Sallusto’s group was first to show that human Th17 cells producing IL-10 in conjunction with IL-17 have specificity for *Staphylococcus aureus* infection⁶³. Conversely, Th17 cells that do not produce IL-10, but instead produce IFN γ with IL-17, have specificity for *Candida albicans* infection, suggesting that, evolutionarily, Th17 cells may have diverged to acquire different cytokine profiles, to become more adept in defense against specific pathogens⁶³. This is in line with clinical observations with immune-deficient patients, where the loss of transcription factor Stat3, which inhibits development of all Th17 cells, results in hyper IgE syndrome and the patients develop rampant *C. albicans* and *S. aureus* infections⁶⁴. Thus, based on our study, we’ve uncovered an interesting overlap in the gene expression profiles of Th17 cells specific for *C. albicans* or *S. aureus* in humans with pathogenic *versus* non-pathogenic Th17 cells in mice. The gene expression profile revealing an IL-17/IFN γ signature which was specific for *C. albicans* in humans had similarities to more pathogenic pro-inflammatory

murine Th17 cells which cause severe EAE. Conversely, the gene profile for IL-17/IL-10-producing Th17 cells specific for *S. aureus* were comparable to a more non-pathogenic, regulatory gene signature^{53,54}. This was highly suggestive of how evolutionary pressures have fine-tuned different effector cells for clearing different types of pathogens and utilized the same cells for the induction of tissue inflammation or to mediate tissue protection, albeit with small changes in the transcriptome.

Challenges in understanding the functional outcome of Th17 heterogeneity

It has become clear in recent years that Th17 cells may have divergent functions⁵³. We are just beginning to understand the functional consequences of this extensive heterogeneity of Th17 cells⁶⁵. Though gene expression profiling has endowed us with the ability to identify a signature that distinguishes pathogenic from non-pathogenic Th17 cells⁵³, we do not know how these cells are naturally derived *in vivo* or what their function is in mediating tissue homeostasis, effector function, inflammation or cancer. For example, do these pathogenic or non-pathogenic Th17 cells develop simultaneously during differentiation in the lymphoid tissue or is there plasticity in the development of Th17 cells such that they can inter-convert based on the environmental cues they receive? Or perhaps there is a sequential development: do non-pathogenic Th17 cells convert into pathogenic Th17 cells during the course of maturation or differentiation? Also, given that the location of the IL-17 producing cells in the peripheral tissue is critical in dictating their function, this raises the issue of how much the peripheral tissue microenvironment alters the developmental programming of Th17 cells. Much remains to be understood in terms of how and why Th17 cells retain heterogeneity and how it influences their functional states.

In recent years, examination of heterogeneity at a single-cell resolution has become possible by high throughput single-cell RNA sequencing of whole genomes and transcriptomes^{66,67}. Single-cell RNA sequencing allows for profiling and characterization of expression variability on a genomic scale, which provides us with the ability to correlate this genomic heterogeneity with functional differences in Th17 cells^{68,69}. In fact, single-cell RNA sequencing of Th17 cells obtained from different tissues and lymphoid organs is allowing identification of novel regulators of functional states (pathogenic *versus* non-pathogenic) of Th17 cells (unpublished observation from our lab). Transcriptomic analysis of T cells in the secondary lymphoid organs following activation does provide valuable clues into the differentiation state acquired by the T cells, but it does not identify the functional state that may be attained

by Th17 cells upon arrival into the tissue niche. The functional states (pathogenic/non-pathogenic) of the Th17 cells may be partly dependent on the cytokine milieu and tissue microenvironment to which the cells migrate in order to mediate effector functions. Utilizing the pathogenicity gene signature derived from our earlier studies⁵³ as one of the definable parameters used to analyze single-cell sequence data, our lab has discovered that the functional states of Th17 cells may be in constant flux as the T cells mediate tissue inflammation (unpublished observation). Uncovering key regulators that control effector functions of Th17 cells may permit novel treatment approaches for therapeutically inhibiting inflammation without affecting the protective functions of Th17 cells.

However, assigning function to these novel regulators will require genetic manipulation undertaken at a large scale. Unfortunately, the only way to confirm the function of a gene is through the use of knockout mice or genetic knockdowns in the cells and disease models^{65,70}. The use of viral vectors or transfection-based si-RNA delivery was not effective in this endeavor, due to the changes in either the differentiation or cell viability induced by these manipulations^{71,72}. Also, to generate a knockout mouse of every novel regulator identified at a single-cell level is an impossible undertaking. To bypass these obvious limitations, our lab in collaboration with Hongkun Park's lab has developed a novel system of silicon nanowire perturbations where newly discovered candidate genes can be knocked-down at a large scale, which has improved the process of functional validation⁶⁵. Silicon nanowire perturbation allows for the delivery of siRNA effectively and efficiently into native T cells without the burden of activation or differentiation^{65,73,74}.

The future

Armed with next-generation sequencing and silicon nanowire knockdowns, the pathogenic potential of subpopulations within Th17 cells can be revealed and novel regulators that may drive functional heterogeneity can be effectively established. Understanding the epigenetic and transcriptional controls of various functional states of Th17 cells will undoubtedly reveal new treatment paradigms for autoimmune diseases as well as give us deeper insight into the complex network that drives inflammatory *versus* tissue-protective functions of Th17 cells.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Khader SA, Gopal R: **IL-17 in protective immunity to intracellular pathogens.** *Virulence*. 2010; 1(5): 423–427.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Khader SA, Guglani L, Rangel-Moreno J, *et al.*: **IL-23 is required for long-term control of *Mycobacterium tuberculosis* and B cell follicle formation in the infected lung.** *J Immunol*. 2011; 187(10): 5402–5407.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mosmann TR, Coffman RL: **TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.** *Annu Rev Immunol*. 1989; 7: 145–173.
[PubMed Abstract](#) | [Publisher Full Text](#)
- King C, Tangye SG, Mackay CR: **T follicular helper (T_{fh}) cells in normal and dysregulated immune responses.** *Annu Rev Immunol*. 2008; 26: 741–766.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Zhu J, Paul WE: **Heterogeneity and plasticity of T helper cells.** *Cell Res*. 2010; 20(1): 4–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zhu J, Yamane H, Paul WE: **Differentiation of effector CD4 T cell populations (*).**

- Annu Rev Immunol.* 2010; **28**: 445–489.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Cox CA, Shi G, Yin H, *et al.*: **Both Th1 and Th17 are immunopathogenic but differ in other key biological activities.** *J Immunol.* 2008; **180**(11): 7141–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 8. Zamvil SS, Steinman L: **The T lymphocyte in experimental allergic encephalomyelitis.** *Annu Rev Immunol.* 1990; **8**: 579–621.
[PubMed Abstract](#) | [Publisher Full Text](#)
 9. Panitch HS, Hirsch RL, Haley AS, *et al.*: **Exacerbations of multiple sclerosis in patients treated with gamma interferon.** *Lancet.* 1987; **1**(8538): 893–895.
[PubMed Abstract](#) | [Publisher Full Text](#)
 10. Wolf SF, Temple PA, Kobayashi M, *et al.*: **Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.** *J Immunol.* 1991; **146**(9): 3074–3081.
[PubMed Abstract](#)
 11. Stern AS, Magram J, Presky DH: **Interleukin-12 an integral cytokine in the immune response.** *Life Sci.* 1996; **58**(8): 639–654.
[PubMed Abstract](#) | [Publisher Full Text](#)
 12. Chua AO, Chizzonite R, Desai BB, *et al.*: **Expression cloning of a human IL-12 receptor component. A new member of the cytokine receptor superfamily with strong homology to gp130.** *J Immunol.* 1994; **153**(1): 128–136.
[PubMed Abstract](#)
 13. Presky DH, Yang H, Minetti LJ, *et al.*: **A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits.** *Proc Natl Acad Sci U S A.* 1996; **26**(24): 14002–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 14. Gately MK, Renzetti LM, Magram J, *et al.*: **The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses.** *Annu Rev Immunol.* 1998; **16**: 495–521.
[PubMed Abstract](#) | [Publisher Full Text](#)
 15. Szabo SJ, Kim ST, Costa GL, *et al.*: **A novel transcription factor, T-bet, directs Th1 lineage commitment.** *Cell.* 2000; **100**(6): 655–669.
[PubMed Abstract](#) | [Publisher Full Text](#)
 16. Brok Herbert PM, van Meurs M, Blezer E, *et al.*: **Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody.** *J Immunol.* 2002; **169**(11): 6554–6563.
[PubMed Abstract](#) | [Publisher Full Text](#)
 17. **F** Langrish CL, Chen Y, Blumenschein WM, *et al.*: **IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.** *J Exp Med.* 2005; **201**(2): 233–240.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 18. Gran B, Zhang G, Yu S, *et al.*: **IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination.** *J Immunol.* 2002; **169**(12): 7104–7110.
[PubMed Abstract](#) | [Publisher Full Text](#)
 19. **F** Becher B, Durell BG, Noelle RJ: **Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12.** *J Clin Invest.* 2002; **110**(4): 493–497.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 20. Zhang G, Gran B, Yu S, *et al.*: **Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system.** *J Immunol.* 2003; **170**(4): 2153–2160.
[PubMed Abstract](#) | [Publisher Full Text](#)
 21. **F** Willenborg DO, Fordham S, Bernard CC, *et al.*: **IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis.** *J Immunol.* 1996; **157**(8): 3223–3227.
[PubMed Abstract](#) | [F1000 Recommendation](#)
 22. **F** Ferber IA, Brocke S, Taylor-Edwards C, *et al.*: **Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE).** *J Immunol.* 1996; **156**(1): 5–7.
[PubMed Abstract](#) | [F1000 Recommendation](#)
 23. Oppmann B, Lesley R, Blom B, *et al.*: **Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.** *Immunity.* 2000; **13**(5): 715–725.
[PubMed Abstract](#) | [Publisher Full Text](#)
 24. Langrish CL, McKenzie BS, Wilson NJ, *et al.*: **IL-12 and IL-23: master regulators of innate and adaptive immunity.** *Immunol Rev.* 2004; **202**(1): 96–105.
[PubMed Abstract](#) | [Publisher Full Text](#)
 25. **F** Cua DJ, Sherlock J, Chen Y, *et al.*: **Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain.** *Nature.* 2003; **421**(6924): 744–748.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 26. Croxford AL, Mair F, Becher B: **IL-23: one cytokine in control of autoimmunity.** *Eur J Immunol.* 2012; **42**(9): 2263–2273.
[PubMed Abstract](#) | [Publisher Full Text](#)
 27. Aggarwal S, Ghilardi N, Xie M, *et al.*: **Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17.** *J Biol Chem.* 2003; **278**(3): 1910–1914.
[PubMed Abstract](#) | [Publisher Full Text](#)
 28. Diveu C, McGeachy MJ, Cua DJ: **Cytokines that regulate autoimmunity.** *Curr Opin Immunol.* 2008; **20**(6): 663–668.
[PubMed Abstract](#) | [Publisher Full Text](#)
 29. **F** Murphy CA, Langrish CL, Chen Y, *et al.*: **Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation.** *J Exp Med.* 2003; **198**(12): 1951–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 30. **F** Uhlig HH, McKenzie BS, Hue S, *et al.*: **Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.** *Immunity.* 2006; **25**(2): 309–318.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 31. **F** Bettelli E, Carrier Y, Gao W, *et al.*: **Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.** *Nature.* 2006; **441**(7090): 235–238.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 32. **F** Mangan PR, Harrington LE, O'Quinn DB, *et al.*: **Transforming growth factor-beta induces development of the TH17 lineage.** *Nature.* 2006; **441**(7090): 231–234.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 33. **F** Veldhoen M, Hocking RJ, Atkins CJ, *et al.*: **TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells.** *Immunity.* 2006; **24**(2): 179–189.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 34. **F** Cargill M, Schrodi SJ, Chang M, *et al.*: **A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.** *Am J Hum Genet.* 2007; **80**(2): 273–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 35. Rahman P, Inman RD, Gladman DD, *et al.*: **Association of interleukin-23 receptor variants with ankylosing spondylitis.** *Arthritis Rheum.* 2008; **58**(4): 1020–1025.
[PubMed Abstract](#) | [Publisher Full Text](#)
 36. Rahman P, Inman RD, Maksymowych WP, *et al.*: **Association of interleukin 23 receptor variants with psoriatic arthritis.** *J Rheumatol.* 2009; **36**(1): 137–140.
[PubMed Abstract](#) | [Publisher Full Text](#)
 37. **F** Huber AK, Jacobson EM, Jazdzewski K, *et al.*: **Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity.** *J Clin Endocrinol Metab.* 2008; **93**(3): 1077–1081.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 38. Ali S, Srivastava AK, Chopra R, *et al.*: **IL12B SNPs and copy number variation in IL23R gene associated with susceptibility to leprosy.** *J Med Genet.* 2013; **50**(1): 34–42.
[PubMed Abstract](#) | [Publisher Full Text](#)
 39. Núñez C, Dema B, Cénit MC, *et al.*: **IL23R: a susceptibility locus for celiac disease and multiple sclerosis?** *Genes Immun.* 2008; **9**(4): 289–293.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Eiris N, González-Lara L, Santos-Juanes J, *et al.*: **Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus.** *J Dermatol Sci.* 2014; **75**(3): 167–172.
[PubMed Abstract](#) | [Publisher Full Text](#)
 41. **F** Hofstetter HH, Ibrahim SM, Koczan D, *et al.*: **Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.** *Cell Immunol.* 2005; **237**(2): 123–130.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 42. **F** Luger D, Silver PB, Tang J, *et al.*: **Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.** *J Exp Med.* 2008; **205**(4): 799–810.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 43. **F** Genovese MC, Van den Bosch F, Roberson SA, *et al.*: **LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study.** *Arthritis Rheum.* 2010; **62**(4): 929–939.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 44. **F** Huh JR, Leung MW, Huang P, *et al.*: **Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity.** *Nature.* 2011; **472**(7344): 486–490.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 45. Xiao S, Yosef N, Yang J, *et al.*: **Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms.** *Immunity.* 2014; **40**(4): 477–489.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 46. Maddur MS, Miossec P, Kaveri SV, *et al.*: **Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies.** *Am J Pathol.* 2012; **181**(1): 8–18.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. **F** Hueber W, Sands BE, Lewitzky S, *et al.*: **Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.** *Gut.* 2012;

- 61(12): 1693–1700.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
48. Kamada N, Seo S, Chen GY, *et al.*: **Role of the gut microbiota in immunity and inflammatory disease.** *Nat Rev Immunol.* 2013; **13**(5): 321–335.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. **F** Atarashi K, Nishimura J, Shima T, *et al.*: **ATP drives lamina propria T_H17 cell differentiation.** *Nature.* 2008; **455**(7214): 808–812.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 50. **F** Ivanov II, Frutos Rde L, Manel N, *et al.*: **Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine.** *Cell Host Microbe.* 2008; **4**(4): 337–349.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 51. **F** O'Connor W Jr, Kamanaka M, Booth CJ, *et al.*: **A protective function for interleukin 17A in T cell-mediated intestinal inflammation.** *Nat Immunol.* 2009; **10**(6): 603–609.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 52. O'Connor W Jr, Zenevich LA, Flavell RA: **The dual nature of T_H17 cells: shifting the focus to function.** *Nat Immunol.* 2010; **11**(6): 471–476.
[PubMed Abstract](#) | [Publisher Full Text](#)
 53. **F** Lee Y, Awasthi A, Yosef N, *et al.*: **Induction and molecular signature of pathogenic T_H17 cells.** *Nat Immunol.* 2012; **13**(10): 991–999.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 54. **F** Ghoreschi K, Laurence A, Yang X, *et al.*: **Generation of pathogenic T_H17 cells in the absence of TGF- β signalling.** *Nature.* 2010; **467**(7318): 967–971.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 55. **F** McGeachy MJ, Bak-Jensen KS, Chen Y, *et al.*: **TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T_H17 cell-mediated pathology.** *Nat Immunol.* 2007; **8**(12): 1390–1397.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 56. McGeachy MJ, Cua DJ: **Th17 cell differentiation: the long and winding road.** *Immunity.* 2008; **28**(4): 445–453.
[PubMed Abstract](#) | [Publisher Full Text](#)
 57. Korn T, Bettelli E, Oukka M, *et al.*: **IL-17 and Th17 Cells.** *Annu Rev Immunol.* 2009; **27**: 485–517.
[PubMed Abstract](#) | [Publisher Full Text](#)
 58. Jäger A, Dardalhon V, Sobel RA, *et al.*: **Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes.** *J Immunol.* 2009; **183**(11): 7169–7177.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. **F** Codarri L, Gyölvérsi G, Tosevski V, *et al.*: **ROR γ t drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.** *Nat Immunol.* 2011; **12**(6): 560–567.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 60. Duvallet E, Semerano L, Assier E, *et al.*: **Interleukin-23: a key cytokine in inflammatory diseases.** *Ann Med.* 2011; **43**(7): 503–511.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. **F** El-Behi M, Ciric B, Dai H, *et al.*: **The encephalitogenicity of T_H17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF.** *Nat Immunol.* 2011; **12**(6): 568–575.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 62. **F** Chung Y, Chang SH, Martinez GJ, *et al.*: **Critical regulation of early Th17 cell differentiation by interleukin-1 signaling.** *Immunity.* 2009; **30**(4): 576–587.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 63. **F** Zielinski CE, Mele F, Aschenbrenner D, *et al.*: **Pathogen-induced human T_H17 cells produce IFN- γ or IL-10 and are regulated by IL-1 β .** *Nature.* 2012; **484**(7395): 514–518.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 64. **F** Ma CS, Chew GY, Simpson N, *et al.*: **Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3.** *J Exp Med.* 2008; **205**(7): 1551–1557.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 65. **F** Yosef N, Shalek AK, Gaublotte JT, *et al.*: **Dynamic regulatory network controlling T_H17 cell differentiation.** *Nature.* 2013; **496**(7446): 461–468.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 66. Kalisky T, Blainey P, Quake SR: **Genomic analysis at the single-cell level.** *Annu Rev Genet.* 2011; **45**: 431–445.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 67. Blainey PC, Quake SR: **Dissecting genomic diversity, one cell at a time.** *Nat Methods.* 2014; **11**(1): 19–21.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 68. **F** Trombetta JJ, Gennert D, Lu D, *et al.*: **Preparation of Single-Cell RNA-Seq Libraries for Next Generation Sequencing.** *Curr Protoc Mol Biol.* 2014; **107**: 4.22.1–4.22.17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 69. **F** Shalek AK, Satija R, Adiconis X, *et al.*: **Single-cell transcriptomics reveals bimodality in expression and splicing in immune cells.** *Nature.* 2013; **498**(7453): 236–240.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 70. Yosef N, Zalcvar E, Rubinstein AD, *et al.*: **ANAT: a tool for constructing and analyzing functional protein networks.** *Sci Signal.* 2011; **4**(196): p11.
[PubMed Abstract](#) | [Publisher Full Text](#)
 71. Dardalhon V, Herpers B, Noraz N, *et al.*: **Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap.** *Gene Ther.* 2001; **8**(3): 190–198.
[PubMed Abstract](#) | [Publisher Full Text](#)
 72. McManus MT, Haines BB, Dillon CP, *et al.*: **Small interfering RNA-mediated gene silencing in T lymphocytes.** *J Immunol.* 2002; **169**(10): 5754–5760.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. **F** Shalek AK, Robinson JT, Karp ES, *et al.*: **Vertical silicon nanowires as a universal platform for delivering biomolecules into living cells.** *Proc Natl Acad Sci U S A.* 2010; **107**(5): 1870–1875.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 74. **F** Shalek AK, Gaublotte JT, Wang L, *et al.*: **Nanowire-mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia.** *Nano Lett.* 2012; **12**(12): 6498–6504.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Dan R. Littman**

New York University School of Medicine, New York, USA

Competing Interests: No competing interests were disclosed.

2. **Jagadeesh Bayry**

French National Institute of Health and Research, Paris, France

Competing Interests: No competing interests were disclosed.

3. **Richard Flavell**

Yale School of Medicine, Connecticut, USA

Nicola Gagliani

Yale School of Medicine, Connecticut, USA

Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research